Cargando…

Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6

BACKGROUND: Prostate cancer is a leading cause of death in the male population of the western world. Human kallikrein-related peptidase 2 (hK2) is abundantly expressed in malignant prostatic tissue, and its gene, KLK2, is regulated by the androgen receptor. 11B6 is a murine IgG(1) monoclonal antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmermand, Oskar Vilhelmsson, Ulmert, David, Evans-Axelsson, Susan, Pettersson, Kim, Bjartell, Anders, Lilja, Hans, Strand, Sven-Erik, Tran, Thuy A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452661/
https://www.ncbi.nlm.nih.gov/pubmed/26116115
http://dx.doi.org/10.1186/s13550-014-0051-5
_version_ 1782374334537400320
author Timmermand, Oskar Vilhelmsson
Ulmert, David
Evans-Axelsson, Susan
Pettersson, Kim
Bjartell, Anders
Lilja, Hans
Strand, Sven-Erik
Tran, Thuy A
author_facet Timmermand, Oskar Vilhelmsson
Ulmert, David
Evans-Axelsson, Susan
Pettersson, Kim
Bjartell, Anders
Lilja, Hans
Strand, Sven-Erik
Tran, Thuy A
author_sort Timmermand, Oskar Vilhelmsson
collection PubMed
description BACKGROUND: Prostate cancer is a leading cause of death in the male population of the western world. Human kallikrein-related peptidase 2 (hK2) is abundantly expressed in malignant prostatic tissue, and its gene, KLK2, is regulated by the androgen receptor. 11B6 is a murine IgG(1) monoclonal antibody directed against free human hK2. In this study, we performed a preclinical evaluation of (111)In-labelled 11B6 in mouse xenografts to investigate its potential in the clinical staging and assessment of metastatic prostate cancer. METHODS: 11B6 was radiolabelled with (111)In through CHX-A″-DTPA chelation. In vivo biodistribution and uptake of (111)In-DTPA-11B6 were measured until 168 h post-injection in NMRI nude mice bearing subcutaneous LNCaP xenografts. The binding specificity to hK2 was evaluated by both in vivo competitive binding assays with excess non-labelled 11B6 and hK2-negative DU145 xenografts. SPECT/CT imaging of subcutaneous and intra-tibial LNCaP xenografts was used to visualize the tumours. RESULTS: Tumour uptake of (111)In-DTPA-11B6 in LNCaP xenografts was 19% ± 0.78%IA/g at 48 h, giving a tumour-to-blood ratio of 1.6, which increases to 2.4 at 1 week post-injection. Accumulation was low in other organs except for the salivary glands, which is probably the result of cross-reactivity with mouse kallikreins. Significantly lower tumour accumulation was observed in competitive assays and DU145 xenografts. SPECT/CT imaging could clearly visualize the subcutaneous and intra-tibial LNCaP xenografts. CONCLUSIONS: Our study demonstrates the potential of (111)In-DTPA-11B6 for the detection of metastatic prostate cancer and monitoring anti-androgen therapy, as it exhibits an increased uptake and accumulation in viable tumour when compared to normal tissue. A humanised version of the 11B6 monoclonal antibody is currently under evaluation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-014-0051-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4452661
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44526612015-06-09 Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6 Timmermand, Oskar Vilhelmsson Ulmert, David Evans-Axelsson, Susan Pettersson, Kim Bjartell, Anders Lilja, Hans Strand, Sven-Erik Tran, Thuy A EJNMMI Res Original Research BACKGROUND: Prostate cancer is a leading cause of death in the male population of the western world. Human kallikrein-related peptidase 2 (hK2) is abundantly expressed in malignant prostatic tissue, and its gene, KLK2, is regulated by the androgen receptor. 11B6 is a murine IgG(1) monoclonal antibody directed against free human hK2. In this study, we performed a preclinical evaluation of (111)In-labelled 11B6 in mouse xenografts to investigate its potential in the clinical staging and assessment of metastatic prostate cancer. METHODS: 11B6 was radiolabelled with (111)In through CHX-A″-DTPA chelation. In vivo biodistribution and uptake of (111)In-DTPA-11B6 were measured until 168 h post-injection in NMRI nude mice bearing subcutaneous LNCaP xenografts. The binding specificity to hK2 was evaluated by both in vivo competitive binding assays with excess non-labelled 11B6 and hK2-negative DU145 xenografts. SPECT/CT imaging of subcutaneous and intra-tibial LNCaP xenografts was used to visualize the tumours. RESULTS: Tumour uptake of (111)In-DTPA-11B6 in LNCaP xenografts was 19% ± 0.78%IA/g at 48 h, giving a tumour-to-blood ratio of 1.6, which increases to 2.4 at 1 week post-injection. Accumulation was low in other organs except for the salivary glands, which is probably the result of cross-reactivity with mouse kallikreins. Significantly lower tumour accumulation was observed in competitive assays and DU145 xenografts. SPECT/CT imaging could clearly visualize the subcutaneous and intra-tibial LNCaP xenografts. CONCLUSIONS: Our study demonstrates the potential of (111)In-DTPA-11B6 for the detection of metastatic prostate cancer and monitoring anti-androgen therapy, as it exhibits an increased uptake and accumulation in viable tumour when compared to normal tissue. A humanised version of the 11B6 monoclonal antibody is currently under evaluation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13550-014-0051-5) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2014-09-19 /pmc/articles/PMC4452661/ /pubmed/26116115 http://dx.doi.org/10.1186/s13550-014-0051-5 Text en © Vilhelmsson Timmermand et al.; licensee Springer. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Original Research
Timmermand, Oskar Vilhelmsson
Ulmert, David
Evans-Axelsson, Susan
Pettersson, Kim
Bjartell, Anders
Lilja, Hans
Strand, Sven-Erik
Tran, Thuy A
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title_full Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title_fullStr Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title_full_unstemmed Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title_short Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6
title_sort preclinical imaging of kallikrein-related peptidase 2 (hk2) in prostate cancer with a (111)in-radiolabelled monoclonal antibody, 11b6
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452661/
https://www.ncbi.nlm.nih.gov/pubmed/26116115
http://dx.doi.org/10.1186/s13550-014-0051-5
work_keys_str_mv AT timmermandoskarvilhelmsson preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT ulmertdavid preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT evansaxelssonsusan preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT petterssonkim preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT bjartellanders preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT liljahans preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT strandsvenerik preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6
AT tranthuya preclinicalimagingofkallikreinrelatedpeptidase2hk2inprostatecancerwitha111inradiolabelledmonoclonalantibody11b6